project id: TCGA-MESO; case submitter id: TCGA-TS-A7P3; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wgs: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.84; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.21; rna integrity number: 7.9; age at index: 57; days to birth: -20964; days to death: 689; ethnicity: not reported; gender: male; race: white; vital status: Dead; year of birth: 1954; year of death: 2012; age at diagnosis: 20964; ajcc pathologic m: MX; ajcc pathologic n: N2; ajcc pathologic stage: Stage III; ajcc pathologic t: T3; ajcc staging system edition: 6th; classification of tumor: not reported; days to diagnosis: 0; icd 10 code: C45.0; last known disease status: not reported; morphology: 9052/3; primary diagnosis: Epithelioid mesothelioma, malignant; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Pleura, NOS; synchronous malignancy: No; tissue or organ of origin: Pleura, NOS; tumor grade: Not Reported; year of diagnosis: 2011; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 917; days to sample procurement: 0; initial weight: 300.0; portion submitter id: TCGA-TS-A7P3-01A-12; percent lymphocyte infiltration: 40.0; percent monocyte infiltration: 20.0; percent necrosis: 20.0; percent neutrophil infiltration: 20.0; percent normal cells: 0.0; percent stromal cells: 20.0; percent tumor cells: 60.0; percent tumor nuclei: 60.0;